Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (Astronomer) trial

Circulation

Volumn 121, Issue 2, 2010, Pages 306-314

  Chan, Kwan Leung ^a   Teo, Koon ^b   Dumesnil, Jean G ^c   Ni, Andy ^d   Tam, James ^e  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b HSC   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Cholesterol; Echocardiography; Lipids; Trials; Valves

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ROSUVASTATIN;

ADULT; ANGINA PECTORIS; AORTA STENOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; CHOLESTEROL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT FAILURE; YOUNG ADULT;

EID: 74949091630     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.900027     Document Type: Article

References (33)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
2. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220-1225.
3. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;9:2262-2270.
4. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;24:3290-3295.
5. Otto C, Kuusisto J, Reichenback DD, Gown AM, O'Brien KD. Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation. 1994;90: 844-853.
6. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996;16:523-532.
7. Olsson M, Dalsgaard C-J, Haegerstrand A, Rosenqvist M, Ryden L, Lilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol. 1994;23:1162-1170.
8. Olsson M. Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218-1222.
9. Rajamannan NM, Subramaniam M, Caira F, Stock Sr, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005; 112(suppl):I-229-I-234.
10. Miller JD, Weiss RM, Serrano KM, Brooks RM, Berry CJ, Zimmerman K, Young SG, Heistad DD. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation. 2009;119: 2693-2701.
11. Hoagland PM, Cook F, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for present of aortic stenosis in adults (age 50 years or older). Am J Cardiol. 1985;55:744-747.
12. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors: a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995-999.
13. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15:865-870.
14. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;3:630-634.
15. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart. 1997;78:475-479.
16. Ghani M, Burwash I, Woodend K, Chan K. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol. 2001;88:690-693.
17. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000; 101:2497-2502.
18. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2005-2009.
19. Bellamy MF, Pellikka PA, Klarich K, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723-1730.
20. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291-1295.
21. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, for the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
22. Rossebo AB, Pedersen TF, Boman, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skaerpe T, Wachtell K, Willenheimer R, for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
23. Chan KL, Teo K, Tam J, Dumesnil JG, for the ASTRONOMER Investigators. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J. 2007;153: 925-931.
24. Fodor JG, Frohlich JJ, Genest JJG Jr, McPherson PR, for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia: report on the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ. 2000;162:1441-1447.
25. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330-341.
26. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611-617.
27. Kawaguchi A, Miyatake K, Yutani C, Beppu S, Tsushima M, Yamamura T, Yamamoto A. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am Heart J. 1999;137:410-418.
28. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerosis involvement of the aortic valve and root in familial hypercholesterolemia. Heart. 1998;80:583-590.
29. Moura LM, Ramos SF, Somorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM. Rosuvastatin affecting aortic valve en-dothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
30. Dichtl W, Franz H, Feuchtner GM, Hintringer F, Reinthaler M, Bartel T, Sussenbacher A, Grander W, Ulmer H, Pachinger O, Muller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg) Am J Cardiol. 2008;102:743-748.
31. Pstay BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-lowering drugs. JAMA. 2008;299:1474-1476.
32. Roberts WC, Ko JM, Hamilton C. Comparison of valve structure, valve weight, and severity of the valve obstruction in 1849 patients having isolated aortic valve replacement of for aortic valve stenosis (with or without associated aortic regurgitation) studied at 3 different medical centres in 2 different time periods. Circulation. 2005;112:3919-3929.
33. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.